Product Information

CLINDA-TRETINOIN 1.2%-0.025% is a generic product labeled by Encube Ethicals, Inc., priced at $3.6177 per GM under NDC 21922005007. Its NADAC has been published 135 times since Apr 17, 2024.

FDA first approved this application on Sep 1, 2023. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CLINDA-TRETINOIN 1.2%-0.025%

Clindamycin Phosphate and Tretinoin Gel 1.2%/0.025%
$3.6177per GM

Strength

10; .25 mg/g; mg/g

NDC

21922005007

Classification

Generic

Dosage Form

GEL

Route

TOPICAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA216943

FDA Approved

9/1/2023

TE Code

AB2

On Market Since

9/4/2023

Pharmacological Classes

Decreased Sebaceous Gland Activity
Lincosamide Antibacterial
Lincosamides
Neuromuscular Blockade
Retinoid
Retinoids

Price Statistics

The NADAC for CLINDA-TRETINOIN 1.2%-0.025% has been published 135 times since Apr 17, 2024, and over the history we have for it it has declined 32.2%. The table below summarizes its recorded NADAC range and movement.

Current price$3.6177 per GM
All-time high$6.9072 (Aug 13, 2025)
All-time low$3.3975 (Aug 19, 2026)
52-week high$5.8987
52-week low$3.3975
Median price$5.0812
Average price$4.9941
Largest weekly change-19.3% (Mar 18, 2026)
Weeks tracked135
Tracking sinceApr 17, 2024

Price History

1W

0.0%

1M

+3.2%

3M

+3.4%

6M

+5.1%

1Y

-38.7%

3Y

N/A

5Y

N/A

All

-32.2%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CLINDA-TRETINOIN 1.2%-0.025%?

The current National Average Drug Acquisition Cost (NADAC) for CLINDA-TRETINOIN 1.2%-0.025%, manufactured by Encube Ethicals, Inc., is $3.6177 per GM (NDC 21922005007), effective Nov 11, 2026.

How has the price of CLINDA-TRETINOIN 1.2%-0.025% changed over time?

Over the history we have for it, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has declined 32.2%. It has been tracked across 135 weekly CMS publications since Apr 17, 2024.

What are the highest and lowest recorded NADAC prices for CLINDA-TRETINOIN 1.2%-0.025%?

Since Apr 17, 2024, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has ranged from a low of $3.3975 (Aug 19, 2026) to a high of $6.9072 (Aug 13, 2025), with a median of $5.0812 per GM.

Are there cheaper alternatives to CLINDA-TRETINOIN 1.2%-0.025%?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CLINDA-TRETINOIN 1.2%-0.025% in a comparable dosage form, but none are currently priced below it.

Who manufactures CLINDA-TRETINOIN 1.2%-0.025%?

CLINDA-TRETINOIN 1.2%-0.025% (NDC 21922005007) is labeled by Encube Ethicals, Inc., and CMS classifies it as a generic product.